AVAlex Volkov

Alex Volkov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alex Volkov has a total of 74 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Mutations in PPCS, Encoding Phosphopantothenoylcysteine Synthetase, Cause Autosomal-Recessive Dilated Cardiomyopathy

    by Arcangela Iuso, Marit Wiersma, Hans-Joachim Schüller, Ben Pode-Shakked, Dina Marek-Yagel, Mathias Grigat, Thomas Schwarzmayr, Riccardo Berutti, Bader Alhaddad, Bart Kanon, et al.


  • Tuftsin–phosphorylcholine (TPC) equally effective to methylprednisolone in ameliorating lupus nephritis in a mice model

    by Asaf Shemer, Shay Kivity, Ora Shovman, T Bashi, Ori Perry, Abdulla Watad, Dana Ben‐Ami Shor, Alex Volkov, Iris Barshack, Nicola L. Bragazzi, et al.

    BACKGROUND: The role of helminth treatment in autoimmune diseases is constantly growing. Systemic lupus erythematosus (SLE) is a multi‐system autoimmune disease with challenging treatment options. Tuftsin phosphorylcholine (TPC) is a novel helminth‐based compound that modulates the host immune network. OBJECTIVES: This study was conducted to evaluate the potential value of TPC in ameliorating lupus nephritis in a murine model and specifically to compare the efficacy of TPC to the existing first‐line therapy for SLE: corticosteroids (methylprednisolone). STUDY DESIGN AND METHODS: Lupus‐prone NZBxW/F1mice were treated with TPC (5 µg/mouse), methylprednisolone (MP; 5mg/body weight) or PBS (control) three times per week once glomerulonephritis, defined as proteinuria of grade > 100 mg/dL, was established. Levels of anti‐dsDNA autoantibodies were evaluated by ELISA, splenic cytokines were measured in‐vitro, and the kidney microscopy was analyzed following staining. RESULTS: TPC and MP treatments significantly improved lupus nephritis and prolonged survival in NZBxW/F1 mice. TPC‐treated mice showed a significantly decreased level of proteinuria (p<0.001) and anti‐dsDNA antibodies (p<0.001) as compared to PBS‐treated mice. Moreover, TPC and MP inhibited the production of the pro‐inflammatory cytokines IFN‐γ, IL‐1β, and IL‐6 (p<0.001) and enhanced expression of the anti‐inflammatory cytokine IL‐10 (p<0.001). Finally, microscopy analysis of the kidneys demonstrated that TPC‐treated mice maintained normal structure equally to MP‐treated mice. CONCLUSIONS: This data indicates that the small molecule named TPC hinders lupus development in genetically lupus‐prone mice equally as methylprednisolone in most of the cases. Hence, TCP may be employed as a therapeutic potential for lupus nephritis.


  • Novel therapeutic compound tuftsin–phosphorylcholine attenuates collagen-induced arthritis

    by Tomer Bashi, Ora Shovman, Mati Fridkin, Alex Volkov, Iris Barshack, Miri Blank, Yehuda Shoenfeld

    Summary: Treatment with helminthes and helminthes ova improved the clinical symptoms of several autoimmune diseases in patients and in animal models. Phosphorylcholine (PC) proved to be the immunomodulatory molecule. We aimed to decipher the tolerogenic potential of tuftsin–PC (TPC), a novel helminth-based compound in collagen-induced arthritis (CIA) a mouse model of rheumatoid arthritis (RA). CIA DBA/1 mice were treated with TPC subcutaneously (5 µg/0.1 ml) or orally (250 µg/0.1 ml), starting prior to disease induction. The control groups were treated with PBS. Collagen antibodies were tested by enzyme-linked immunosorbent assay (ELISA), cytokine protein levels by ELISA kits and regulatory T (Treg) and regulatory B (Breg) cell phenotypes by fluorescence-activated cell sorter (FACS). TPC-treated mice had a significantly lower arthritis score of 1.5 in comparison with control mice 11.8 (P < 0.0001) in both subcutaneous and orally treated groups at day 31. Moreover, histology analysis demonstrated highly inflamed joints in control mice, whereas TPC-treated mice maintained normal joint structure. Furthermore, TPC decreased the titres of circulating collagen II antibodies in mice sera (P < 0.0001), enhanced expression of IL-10 (P < 0.0001) and inhibited production of tumour necrosis factor (TNF)-α, interleukin (IL)−17 and IL-1β (P < 0.0001). TPC significantly expanded the CD4+CD25+ forkhead box protein 3 (FoxP3+) Treg cells and CD19+IL-10+CD5highCD1dhighT cell immunoglobulin mucin-1 (TIM-1+) Breg cell phenotypes (P < 0.0001) in treated mice. Our data indicate that treatment with TPC attenuates CIA in mice demonstrated by low arthritic score and normal joints histology. TPC treatment reduced proinflammatory cytokines and increased anti-inflammatory cytokine expression, as well as expansion of Treg and Breg cells. Our results may lead to a new approach for a natural therapy for early rheumatoid arthritis onset.


  • Anti-citrullinated-protein-antibody-specific intravenous immunoglobulin attenuates collagen-induced arthritis in mice

    by N. Svetlicky, S. Kivity, Q. Odeh, O. Shovman, S. Gertel, H. Amital, O. Gendelman, A. Volkov, I. Barshack, E. Bar‐Meir, et al.

    Administration of intravenous immunoglobulin (IVIg) is a recognized safe and efficient immunomodulation therapy for many autoimmune diseases. Anti-idiotypic antibody binding to pathogenic autoantibodies was proposed as one of the mechanisms attributed to the protective activity of IVIg in autoimmunity. The aim of this study was to fractionate the anti-anti-citrullinated protein anti-idiotypic-antibodies (anti-ACPA) from an IVIg preparation and to test it as a treatment for collagen-induced arthritis in mice. IVIg was loaded onto an ACPA column. The eluted fraction was defined as ACPA-specific-IVIg (ACPA-sIVIg). Collagen-induced-arthritis (CIA) was induced in mice. Mice were treated weekly with ACPA-sIVIg, low-dose-IVIg, high-dose-IVIg and phosphate-buffered saline (PBS). Sera-ACPA titres, anti-collagen anitbodies and cytokine levels were analysed by enzyme-linked immunosorbent assay (ELISA); antibody-forming-cell activity by enzyme-linked imunospot (ELISPOT) assay; and expansion of regulatory T cell (Treg ) population by fluorescence activated cell sorter (FACS). ACPA-sIVIg inhibited ACPA binding to citrullinated-peptides (CCP) in vitro 100 times more efficiently than the IVIg compound. ACPA-sIVIg was significantly more effective than the IVIg-preparation in attenuating the development of collagen-induced arthritis. Splenocytes from CIA mice treated with ACPA-sIVIg reduced the ACPA and anti-collagen-antibody titres, including the number of anti-collagen and ACPA antibody-forming cells. In parallel, splenocytes from ACPA-sIVIg treated mice secreted higher levels of anti-inflammatory cytokines and lower proinflammatory cytokines. The ACPA-sIVIg inhibitory potential was accompanied with expansion of the Treg population. Low-dose IVIg did not affect the humoral and cellular response in the CIA mice in comparison to the PBS-treated mice. Based on our results, IVIg may be considered as a safe compound for treating patients with rheumatoid arthritis by neutralizing pathogenic autoantibodies, reducing proinflammatory cytokines and expanding the Treg population.


  • Immunization with hepatitis B vaccine accelerates SLE-like disease in a murine model

    by Nancy Agmon-Levin, María-Teresa Arango, Shaye Kivity, Aviva Katzav, Boris Gilburd, Miri Blank, Nir Tomer, Alex Volkov, Iris Barshack, Joab Chapman, et al.


  • Minimal Traumatic Brain Injury Induce Apoptotic Cell Death in Mice

    by V. Tashlykov, Y. Katz, A. Volkov, V. Gazit, S. Schreiber, O. Zohar, C. G. Pick

    In the United States, 1.4 million people suffer from traumatic brain injury (TBI) each year because of traffic, sports, or war-related injuries. The majority of TBI victims suffer mild to minimal TBI (mTBI), but most are released undiagnosed. Detailed pathologies are poorly understood. We characterized the microscopic changes of neurons of closed-head mTBI mice after increased unilateral trauma using hematoxylin and eosin (H&E) stain, and correlated it with the expression of the apoptotic proteins c-jun, p53, and BCL-2. Minimal damage to the brain increases the number of pyknotic appearing neurons and activates the apoptotic proteins in both hemispheres. Although minimal, increased impact was positively correlated with the increased number of damaged neurons. These results may explain the wide variety of behavioral and cognitive deficits closed-head mTBI causes in mice. Our cumulative results point to the pathological origin of post-concussion syndrome and may aid in the development of future neuroprotective strategies for the disease.